世界のコンパニオン腫瘍診断市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Oncology Companion Diagnostic Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5273 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、コンパニオン腫瘍診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、免疫組織化学（IHC）、インサイチューハイブリダイゼーション（ISH）/蛍光インサイチューハイブリダイゼーション（FISH）、その他）、用途別市場規模（病院、病理学/診断研究所、学術医療センター）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・コンパニオン腫瘍診断の市場動向 ・企業の競争状況、市場シェア ・コンパニオン腫瘍診断の種類別市場規模と予測2016-2027（ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、免疫組織化学（IHC）、インサイチューハイブリダイゼーション（ISH）/蛍光インサイチューハイブリダイゼーション（FISH）、その他） ・コンパニオン腫瘍診断の用途別市場規模と予測2016-2027（病院、病理学/診断研究所、学術医療センター） ・コンパニオン腫瘍診断の北米市場規模2016-2027（アメリカ、カナダ） ・コンパニオン腫瘍診断の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・コンパニオン腫瘍診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・コンパニオン腫瘍診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・コンパニオン腫瘍診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Agilent Technologies, Inc.、Illumina, Inc.、Qiagen N.V.、Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd.、ARUP Laboratories、Abbott、Myriad Genetics, Inc.、bioMérieux SA、Invivoscribe, Inc.） ・結論

A companion diagnostic is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.

Market Analysis and Insights: Global Oncology Companion Diagnostic Market
The global Oncology Companion Diagnostic market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncology Companion Diagnostic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncology Companion Diagnostic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncology Companion Diagnostic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncology Companion Diagnostic market.

Global Oncology Companion Diagnostic Scope and Market Size
Oncology Companion Diagnostic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Companion Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others

Segment by Application
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Companion Diagnostic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.2.4 Immunohistochemistry (IHC)
1.2.5 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Oncology Companion Diagnostic Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Pathology/Diagnostic Laboratory
1.3.4 Academic Medical Center
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Oncology Companion Diagnostic Market Perspective (2016-2027)
2.2 Oncology Companion Diagnostic Growth Trends by Regions
2.2.1 Oncology Companion Diagnostic Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oncology Companion Diagnostic Historic Market Share by Regions (2016-2021)
2.2.3 Oncology Companion Diagnostic Forecasted Market Size by Regions (2022-2027)
2.3 Oncology Companion Diagnostic Industry Dynamic
2.3.1 Oncology Companion Diagnostic Market Trends
2.3.2 Oncology Companion Diagnostic Market Drivers
2.3.3 Oncology Companion Diagnostic Market Challenges
2.3.4 Oncology Companion Diagnostic Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Oncology Companion Diagnostic Players by Revenue
3.1.1 Global Top Oncology Companion Diagnostic Players by Revenue (2016-2021)
3.1.2 Global Oncology Companion Diagnostic Revenue Market Share by Players (2016-2021)
3.2 Global Oncology Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oncology Companion Diagnostic Revenue
3.4 Global Oncology Companion Diagnostic Market Concentration Ratio
3.4.1 Global Oncology Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Companion Diagnostic Revenue in 2020
3.5 Oncology Companion Diagnostic Key Players Head office and Area Served
3.6 Key Players Oncology Companion Diagnostic Product Solution and Service
3.7 Date of Enter into Oncology Companion Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Oncology Companion Diagnostic Breakdown Data by Type
4.1 Global Oncology Companion Diagnostic Historic Market Size by Type (2016-2021)
4.2 Global Oncology Companion Diagnostic Forecasted Market Size by Type (2022-2027)

5 Oncology Companion Diagnostic Breakdown Data by Application
5.1 Global Oncology Companion Diagnostic Historic Market Size by Application (2016-2021)
5.2 Global Oncology Companion Diagnostic Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Oncology Companion Diagnostic Market Size (2016-2027)
6.2 North America Oncology Companion Diagnostic Market Size by Type
6.2.1 North America Oncology Companion Diagnostic Market Size by Type (2016-2021)
6.2.2 North America Oncology Companion Diagnostic Market Size by Type (2022-2027)
6.2.3 North America Oncology Companion Diagnostic Market Size by Type (2016-2027)
6.3 North America Oncology Companion Diagnostic Market Size by Application
6.3.1 North America Oncology Companion Diagnostic Market Size by Application (2016-2021)
6.3.2 North America Oncology Companion Diagnostic Market Size by Application (2022-2027)
6.3.3 North America Oncology Companion Diagnostic Market Size by Application (2016-2027)
6.4 North America Oncology Companion Diagnostic Market Size by Country
6.4.1 North America Oncology Companion Diagnostic Market Size by Country (2016-2021)
6.4.2 North America Oncology Companion Diagnostic Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Oncology Companion Diagnostic Market Size (2016-2027)
7.2 Europe Oncology Companion Diagnostic Market Size by Type
7.2.1 Europe Oncology Companion Diagnostic Market Size by Type (2016-2021)
7.2.2 Europe Oncology Companion Diagnostic Market Size by Type (2022-2027)
7.2.3 Europe Oncology Companion Diagnostic Market Size by Type (2016-2027)
7.3 Europe Oncology Companion Diagnostic Market Size by Application
7.3.1 Europe Oncology Companion Diagnostic Market Size by Application (2016-2021)
7.3.2 Europe Oncology Companion Diagnostic Market Size by Application (2022-2027)
7.3.3 Europe Oncology Companion Diagnostic Market Size by Application (2016-2027)
7.4 Europe Oncology Companion Diagnostic Market Size by Country
7.4.1 Europe Oncology Companion Diagnostic Market Size by Country (2016-2021)
7.4.2 Europe Oncology Companion Diagnostic Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Oncology Companion Diagnostic Market Size (2016-2027)
8.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type
8.2.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2027)
8.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application
8.3.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2027)
8.4 Asia-Pacific Oncology Companion Diagnostic Market Size by Region
8.4.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Oncology Companion Diagnostic Market Size (2016-2027)
9.2 Latin America Oncology Companion Diagnostic Market Size by Type
9.2.1 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2021)
9.2.2 Latin America Oncology Companion Diagnostic Market Size by Type (2022-2027)
9.2.3 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2027)
9.3 Latin America Oncology Companion Diagnostic Market Size by Application
9.3.1 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2021)
9.3.2 Latin America Oncology Companion Diagnostic Market Size by Application (2022-2027)
9.3.3 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2027)
9.4 Latin America Oncology Companion Diagnostic Market Size by Country
9.4.1 Latin America Oncology Companion Diagnostic Market Size by Country (2016-2021)
9.4.2 Latin America Oncology Companion Diagnostic Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Oncology Companion Diagnostic Market Size (2016-2027)
10.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type
10.2.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2027)
10.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application
10.3.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2027)
10.4 Middle East & Africa Oncology Companion Diagnostic Market Size by Country
10.4.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Agilent Technologies, Inc.
11.1.1 Agilent Technologies, Inc. Company Details
11.1.2 Agilent Technologies, Inc. Business Overview
11.1.3 Agilent Technologies, Inc. Oncology Companion Diagnostic Introduction
11.1.4 Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.1.5 Agilent Technologies, Inc. Recent Development
11.2 Illumina, Inc.
11.2.1 Illumina, Inc. Company Details
11.2.2 Illumina, Inc. Business Overview
11.2.3 Illumina, Inc. Oncology Companion Diagnostic Introduction
11.2.4 Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.2.5 Illumina, Inc. Recent Development
11.3 Qiagen N.V.
11.3.1 Qiagen N.V. Company Details
11.3.2 Qiagen N.V. Business Overview
11.3.3 Qiagen N.V. Oncology Companion Diagnostic Introduction
11.3.4 Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.3.5 Qiagen N.V. Recent Development
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Company Details
11.4.2 Thermo Fisher Scientific Inc. Business Overview
11.4.3 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Introduction
11.4.4 Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.4.5 Thermo Fisher Scientific Inc. Recent Development
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Company Details
11.5.2 F. Hoffmann-La Roche Ltd. Business Overview
11.5.3 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Introduction
11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
11.6 ARUP Laboratories
11.6.1 ARUP Laboratories Company Details
11.6.2 ARUP Laboratories Business Overview
11.6.3 ARUP Laboratories Oncology Companion Diagnostic Introduction
11.6.4 ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.6.5 ARUP Laboratories Recent Development
11.7 Abbott
11.7.1 Abbott Company Details
11.7.2 Abbott Business Overview
11.7.3 Abbott Oncology Companion Diagnostic Introduction
11.7.4 Abbott Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.7.5 Abbott Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Details
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Oncology Companion Diagnostic Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 bioMérieux SA
11.9.1 bioMérieux SA Company Details
11.9.2 bioMérieux SA Business Overview
11.9.3 bioMérieux SA Oncology Companion Diagnostic Introduction
11.9.4 bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.9.5 bioMérieux SA Recent Development
11.10 Invivoscribe, Inc.
11.10.1 Invivoscribe, Inc. Company Details
11.10.2 Invivoscribe, Inc. Business Overview
11.10.3 Invivoscribe, Inc. Oncology Companion Diagnostic Introduction
11.10.4 Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.10.5 Invivoscribe, Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Oncology Companion Diagnostic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Key Players of Immunohistochemistry (IHC)
Table 5. Key Players of In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Table 6. Key Players of Others
Table 7. Global Oncology Companion Diagnostic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Oncology Companion Diagnostic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Oncology Companion Diagnostic Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Oncology Companion Diagnostic Market Share by Regions (2016-2021)
Table 11. Global Oncology Companion Diagnostic Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Oncology Companion Diagnostic Market Share by Regions (2022-2027)
Table 13. Oncology Companion Diagnostic Market Trends
Table 14. Oncology Companion Diagnostic Market Drivers
Table 15. Oncology Companion Diagnostic Market Challenges
Table 16. Oncology Companion Diagnostic Market Restraints
Table 17. Global Oncology Companion Diagnostic Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Oncology Companion Diagnostic Market Share by Players (2016-2021)
Table 19. Global Top Oncology Companion Diagnostic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Companion Diagnostic as of 2020)
Table 20. Ranking of Global Top Oncology Companion Diagnostic Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Oncology Companion Diagnostic Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Oncology Companion Diagnostic Product Solution and Service
Table 24. Date of Enter into Oncology Companion Diagnostic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Oncology Companion Diagnostic Revenue Market Share by Type (2016-2021)
Table 28. Global Oncology Companion Diagnostic Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Oncology Companion Diagnostic Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Oncology Companion Diagnostic Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Oncology Companion Diagnostic Revenue Market Share by Application (2016-2021)
Table 32. Global Oncology Companion Diagnostic Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Oncology Companion Diagnostic Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Oncology Companion Diagnostic Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Oncology Companion Diagnostic Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Oncology Companion Diagnostic Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Oncology Companion Diagnostic Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Oncology Companion Diagnostic Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Oncology Companion Diagnostic Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Oncology Companion Diagnostic Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Oncology Companion Diagnostic Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Oncology Companion Diagnostic Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Oncology Companion Diagnostic Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Oncology Companion Diagnostic Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Oncology Companion Diagnostic Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Oncology Companion Diagnostic Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Oncology Companion Diagnostic Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Oncology Companion Diagnostic Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2022-2027) & (US$ Million)
Table 64. Agilent Technologies, Inc. Company Details
Table 65. Agilent Technologies, Inc. Business Overview
Table 66. Agilent Technologies, Inc. Oncology Companion Diagnostic Product
Table 67. Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 68. Agilent Technologies, Inc. Recent Development
Table 69. Illumina, Inc. Company Details
Table 70. Illumina, Inc. Business Overview
Table 71. Illumina, Inc. Oncology Companion Diagnostic Product
Table 72. Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 73. Illumina, Inc. Recent Development
Table 74. Qiagen N.V. Company Details
Table 75. Qiagen N.V. Business Overview
Table 76. Qiagen N.V. Oncology Companion Diagnostic Product
Table 77. Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 78. Qiagen N.V. Recent Development
Table 79. Thermo Fisher Scientific Inc. Company Details
Table 80. Thermo Fisher Scientific Inc. Business Overview
Table 81. Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Product
Table 82. Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 83. Thermo Fisher Scientific Inc. Recent Development
Table 84. F. Hoffmann-La Roche Ltd. Company Details
Table 85. F. Hoffmann-La Roche Ltd. Business Overview
Table 86. F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Product
Table 87. F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 88. F. Hoffmann-La Roche Ltd. Recent Development
Table 89. ARUP Laboratories Company Details
Table 90. ARUP Laboratories Business Overview
Table 91. ARUP Laboratories Oncology Companion Diagnostic Product
Table 92. ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 93. ARUP Laboratories Recent Development
Table 94. Abbott Company Details
Table 95. Abbott Business Overview
Table 96. Abbott Oncology Companion Diagnostic Product
Table 97. Abbott Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 98. Abbott Recent Development
Table 99. Myriad Genetics, Inc. Company Details
Table 100. Myriad Genetics, Inc. Business Overview
Table 101. Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 102. Myriad Genetics, Inc. Recent Development
Table 103. bioMérieux SA Company Details
Table 104. bioMérieux SA Business Overview
Table 105. bioMérieux SA Oncology Companion Diagnostic Product
Table 106. bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 107. bioMérieux SA Recent Development
Table 108. Invivoscribe, Inc. Company Details
Table 109. Invivoscribe, Inc. Business Overview
Table 110. Invivoscribe, Inc. Oncology Companion Diagnostic Product
Table 111. Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021) & (US$ Million)
Table 112. Invivoscribe, Inc. Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Companion Diagnostic Market Share by Type: 2020 VS 2027
Figure 2. Polymerase Chain Reaction (PCR) Features
Figure 3. Next-Generation Sequencing (NGS) Features
Figure 4. Immunohistochemistry (IHC) Features
Figure 5. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) Features
Figure 6. Others Features
Figure 7. Global Oncology Companion Diagnostic Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Pathology/Diagnostic Laboratory Case Studies
Figure 10. Academic Medical Center Case Studies
Figure 11. Oncology Companion Diagnostic Report Years Considered
Figure 12. Global Oncology Companion Diagnostic Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Oncology Companion Diagnostic Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Oncology Companion Diagnostic Market Share by Regions: 2020 VS 2027
Figure 15. Global Oncology Companion Diagnostic Market Share by Regions (2022-2027)
Figure 16. Global Oncology Companion Diagnostic Market Share by Players in 2020
Figure 17. Global Top Oncology Companion Diagnostic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Companion Diagnostic as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Oncology Companion Diagnostic Revenue in 2020
Figure 19. Global Oncology Companion Diagnostic Revenue Market Share by Type (2016-2021)
Figure 20. Global Oncology Companion Diagnostic Revenue Market Share by Type (2022-2027)
Figure 21. North America Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Oncology Companion Diagnostic Market Share by Type (2016-2027)
Figure 23. North America Oncology Companion Diagnostic Market Share by Application (2016-2027)
Figure 24. North America Oncology Companion Diagnostic Market Share by Country (2016-2027)
Figure 25. United States Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Oncology Companion Diagnostic Market Share by Type (2016-2027)
Figure 29. Europe Oncology Companion Diagnostic Market Share by Application (2016-2027)
Figure 30. Europe Oncology Companion Diagnostic Market Share by Country (2016-2027)
Figure 31. Germany Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Oncology Companion Diagnostic Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Oncology Companion Diagnostic Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Oncology Companion Diagnostic Market Share by Region (2016-2027)
Figure 41. China Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Oncology Companion Diagnostic Market Share by Type (2016-2027)
Figure 49. Latin America Oncology Companion Diagnostic Market Share by Application (2016-2027)
Figure 50. Latin America Oncology Companion Diagnostic Market Share by Country (2016-2027)
Figure 51. Mexico Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Oncology Companion Diagnostic Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Oncology Companion Diagnostic Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Oncology Companion Diagnostic Market Share by Country (2016-2027)
Figure 57. Turkey Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Oncology Companion Diagnostic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Agilent Technologies, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 61. Illumina, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 62. Qiagen N.V. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 63. Thermo Fisher Scientific Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 64. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 65. ARUP Laboratories Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 66. Abbott Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 67. Myriad Genetics, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 68. bioMérieux SA Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 69. Invivoscribe, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---